Cell and gene therapies are moving towards correcting root causes of diseases. Let's take a look at future cell and gene therapy trends.

The Director of the San Raffaele-Telethon Institute for Gene Therapy Luigi Naldini reflects on what a recent Nature study reveals and about the future of in vivo gene transfer “Our study provides an ...

Though the therapy, Kresladi, isn’t seen as a big seller, its clearance is a step forward for a company that’s lost most of its value since 2021 amid several setbacks.

LC: Manufacturability is the field's most critical near-term challenge, especially for ex vivo cell therapies. Encouragingly, ...

Emerging pathways can help cell and gene therapies become commercially viable for intractable diseases, even with uneven scalability and consistency.

In the five years since Italy-based Chiesi Group established its rare disease division in Boston, the unit has landed regulatory approvals worldwide for 10 therapies — all small molecules and ...

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a ...

SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced ...

Recordati Joins Boehringer Ingelheim Venture Fund in Financing Round, with Participation from Delos and Blue Bay Capital New Investment, Combined with Recent $8.4 Million ARPA-H Award, Brings Funds ...

As Chief Editor of one of the two journals in which Biopharma Dealmakers appears, I have a keen interest in the process of translating biomedical research into new drugs, including the partnerships ...

CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- STRM.BIO, a start-up biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced that it has been ...